CoChat

Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes

Wick, Allison, Newlin, Kelley · 2009 · Journal of the American Academy of Nurse Practitioners
Cited by 13

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Purpose: To highlight the therapeutic promise of the incretin hormone glucagon‐like peptide‐1 (GLP‐1), the consequent rationale for therapies acting through GLP‐1‐mediated pathways in type 2 diabetes mellitus (T2DM), and the emerging clinical role of the dipeptidyl peptidase‐4 (DPP‐4) inhibitors and GLP‐1 receptor agonists. Data sources: The PubMed database was searched (using terms including incretins, GLP‐1, GIP, DPP‐4), along with recent ADA and EASD abstracts. Conclusions: Many traditional drugs used for T2DM fail to achieve and maintain glycemic control, and possess limitations such as risk for hypoglycemia and weight gain. GLP‐1 is a gut‐derived hormone that glucose‐dependently stimulates insulin secretion while simultaneously reducing gastric emptying and appetite. Other physiological actions of GLP‐1 may benefit the cardiovascular system and beta‐cell function. Recently developed drug therapies that mimic or prolong the action of this hormone, therefore, have great promise in the treatment of T2DM. Implications for practice: The GLP‐1 receptor agonists and DPP‐4 inhibitors are incretin‐based therapies that are now becoming established as effective therapies for T2DM to be used either as monotherapy or added to other antidiabetes drugs. They enable improvements to be made in glycemic control without weight gain, with a low risk for hypoglycemia, and with potential additional clinical benefits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1745-7599.2009.00455.x

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Metadata

Authors
Wick, A., & Newlin, K.
Venue
Journal of the American Academy of Nurse Practitioners
Publisher
Wiley
Published
2009-11
Volume
21
Issue
s1
Pages
623-630
ISSN
  • 1041-2972 (ISSN-L)
  • 1745-7599
OpenAlex
W1984177371
Cited by
13
References
14
FWCI
0.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1745-7599.2009.00455.x
The paper
Wick, A., & Newlin, K. (2009). Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes. Journal of the American Academy of Nurse Practitioners. https://doi.org/10.1111/j.1745-7599.2009.00455.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.